Tirzepatide adds GIP receptor activation, which appears to enhance adipose tissue metabolism and amplify weight loss beyond GLP-1 alone
This risk spikes during dose escalations, illness, missed meals, or increased activity
As larger clinical trials continue, clinicians should monitor developments carefully while maintaining realistic expectations about what current evidence actually supports
Observational Adverse Events and Severe Toxicities Conversely, the unregulated, experimental nature of this digital ecosystem has brought significant, highly concerning adverse effects to light, severely underscoring the dangers of self-administering experimental systemic therapeutics
The peptides long-term effects are unknown, and repeated or high-dose use may pose unforeseen risks
Nat Med 8: 13901397, 2002